Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor

Lyudmila Burdelya1, Maciej Kujawski, Guilian Niu

  • 1H. Lee Moffitt Cancer Center and Research Institute and Department of Oncology, College of Medicine, University of South Florida, Tampa, FL 33612, USA.

Insights

Blocking Signal transducer and activator of transcription 3 (Stat3) in melanoma cells enhances immune cell infiltration and activates innate immune responses. This strategy recruits diverse immune cells and promotes anti-tumor activity.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Immune cell infiltration into tumors is crucial for effective anti-tumor immunity.
  • Signal transducer and activator of transcription 3 (Stat3) is frequently activated in cancers, promoting tumor growth.
  • Regulation of immune cell infiltration into tumors is not fully understood.

Purpose of the Study:

  • To investigate the role of Stat3 activity in tumor cells on immune cell infiltration.
  • To explore the potential of blocking Stat3 signaling to enhance anti-tumor immune responses.

Main Methods:

  • Utilized isogenic murine melanoma models.
  • Blocked Stat3 signaling in tumor cells.
  • Analyzed the expression of chemoattractants and immune cell migration.
  • Assessed macrophage activation and nitric oxide (NO) production.
  • Investigated the role of TNF-alpha and IFN-beta in immune activation.

Main Results:

  • Constitutive Stat3 activity in melanoma cells correlated with tumor growth and reduced T cell infiltration.
  • Blocking Stat3 in tumor cells increased the expression of chemoattractants, enhancing the migration of lymphocytes, NK cells, neutrophils, and macrophages.
  • Stat3 inhibition in tumor cells induced the production of soluble factors that activated macrophage nitric oxide (NO) production.
  • Tumor cells treated with Stat3 inhibitors secreted TNF-alpha and IFN-beta, which activated macrophage NO production.

Conclusions:

  • Tumor Stat3 activity influences the recruitment of various immune effector cells.
  • Blocking Stat3 signaling in tumor cells can be a strategy to activate the effector phase of innate immune responses.
  • Stat3 inhibition promotes macrophage-mediated, NO-dependent anti-tumor activity.